Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a cell-permeable, small-molecule inhibitor targeting ROCK1 and ROCK2 with high selectivity (APExBIO). It inhibits ROCK1 with an IC50 of approximately 140 nM and ROCK2 with a Ki of 300 nM, showing over 200-fold selectivity versus other kinases (Luo et al., 2021). Y-27632 suppresses Rho-mediated actin stress fiber formation and modulates cell cycle progression, making it a vital tool for cytoskeletal and stem cell research. The compound demonstrates robust solubility in aqueous and organic solvents, and its bioactivity is supported by in vitro and in vivo benchmarks. Its use has expanded to organoid culture, tumor invasion assays, and stem cell survival optimization.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases involved in the regulation of actin cytoskeleton, cellular contractility, adhesion, and motility. Activation of the Rho/ROCK signaling pathway promotes stress fiber formation, focal adhesion assembly, and cell migration. Dysregulation of this pathway is implicated in pathological conditions including cancer metastasis, fibrosis, and cardiovascular diseases (Luo et al., 2021). Selective inhibition of ROCK1/2 enables researchers to dissect cytoskeletal dynamics, cell proliferation, and invasion mechanisms in a controlled manner. Y-27632 dihydrochloride, as a highly selective ROCK inhibitor, allows for precise modulation of these pathways without significant off-target effects on kinases such as PKC, MLCK, or PAK.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively binds to the ATP-binding site within the catalytic domains of ROCK1 and ROCK2. This binding results in inhibition of kinase activity with reported IC50 values of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 (APExBIO). By blocking ROCK activity, Y-27632 prevents phosphorylation of downstream substrates such as myosin light chain (MLC), LIM kinase, and cofilin. This leads to disrupted assembly of actin stress fibers, altered cell morphology, and reduced cellular contractility. In proliferative contexts, Y-27632 modulates cell cycle progression, especially the G1-S phase transition, and can inhibit cytokinesis. The compound’s >200-fold selectivity versus unrelated kinases ensures minimal interference in parallel signaling pathways, making it a gold standard for Rho/ROCK pathway inhibition (related article).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of 140 nM and ROCK2 with a Ki of 300 nM under in vitro kinase assay conditions (APExBIO).
• It demonstrates >200-fold selectivity against kinases such as PKC, PKA, MLCK, and PAK, as measured by comparative enzymatic assays (Luo et al., 2021).
• In prostatic smooth muscle cells, Y-27632 reduces proliferation rates in a concentration-dependent manner (0.1–10 μM, 37°C, standard culture medium) (Luo et al., 2021).
• Mouse xenograft models treated with Y-27632 (30 mg/kg, intraperitoneal, daily) display reduced tumor invasion and metastasis compared to controls (Luo et al., 2021).
• Organoid cultures established from patient-derived breast tumor tissue exhibit enhanced viability and structural integrity when supplemented with 10 μM Y-27632 during initial passages (Luo et al., 2021).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water; solubility increases with brief warming (37°C) or ultrasonic agitation (APExBIO).

This article extends the mechanistic focus of Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cytoskeletal Research by providing updated benchmarks and a focused discussion on organoid and cancer assay integration. For a systems biology perspective, see Y-27632 Dihydrochloride: Precision ROCK Inhibition as a Strategic Platform, which we clarify here by distinguishing cell-type-specific applications. In contrast to Y-27632 Dihydrochloride: Advanced ROCK Inhibition in Viral Pathogenesis, this article emphasizes tumor biology and stem cell workflows.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used as a tool compound in basic and translational research:

• Cellular Cytoskeletal Studies: Inhibits Rho-mediated actin stress fiber formation, enabling studies on cell shape, migration, and adhesion.
• Stem Cell Culture: Enhances human pluripotent stem cell survival and single-cell passaging, increasing colony formation efficiency.
• Cancer Invasion and Metastasis Assays: Reduces tumor cell migration and invasion in both 2D and 3D systems.
• Organoid Establishment: Improves viability and expansion of patient-derived organoids, especially during initial derivation steps (Luo et al., 2021).
• Cytokinesis and Cell Cycle: Interferes with cytokinesis, facilitating studies on cell division and multinucleation.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; it does not broadly inhibit PKC, MLCK, or PAK at standard concentrations.
• Prolonged exposure (>72 hours) at high concentrations (>30 μM) may result in off-target effects or toxicity.
• Y-27632 does not induce differentiation in stem cells; it primarily enhances survival during stress and passage.
• It cannot reverse established fibrosis or metastatic disease in vivo; effects are preventive/modulatory, not curative.
• Storage of stock solutions at room temperature or repeated freeze-thaw cycles may reduce compound potency.

Workflow Integration & Parameters

For laboratory use, Y-27632 dihydrochloride (APExBIO, SKU: A3008) is supplied as a solid. Dissolution is achieved in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL), with solubility enhanced by warming to 37°C or brief sonication. For cell culture, typical working concentrations range from 1 to 10 μM, with stock solutions stored at or below -20°C and protected from moisture (APExBIO). Long-term storage of aqueous solutions is discouraged. In stem cell applications, Y-27632 is added during cell dissociation and for 24–48 hours post-passage. For cancer invasion assays and organoid establishment, supplementation during initial culture phases is recommended. Users should titrate concentrations for each cell type and endpoint. For additional protocols and troubleshooting, see Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cytoskeletal Studies.

Conclusion & Outlook

Y-27632 dihydrochloride is a rigorously validated, selective ROCK1/2 inhibitor with broad utility in cell biology, cancer, and organoid research. Its high selectivity and solubility profile support reproducible modulation of the Rho/ROCK pathway. Recent benchmarks confirm its value in organoid viability and tumor invasion suppression. As research advances, Y-27632 is expected to remain a cornerstone tool for dissecting cytoskeletal and signaling networks in health and disease (Luo et al., 2021).